You are about to leave the Clinical Value website now.


The clinical utility of Elecsys GAAD score in the diagnosis of hepatocellular carcinoma

The performance of Elecsys® GAAD score, which includes the parameters of gender, age, alpha-fetoprotein (AFP) and protein induced by Vitamin K absence or antagonists-II (PIVKA-II) in the diagnosis of HCC is elusive. This study aims to address the diagnostic accuracy of HCC using Elecsys GAAD algorithmic score as compared to AFP and PIVKA-II with or without the complementation of sonography. Huang CF, Sharma A, Yu ML

Read more

Recent Articles

9 December 2022

Performance Evaluation of the Elecsys GAAD Assay for the Detection of Hepatocellular Carcinoma Across Different Disease Stages and Etiologies

The Elecsys® GAAD algorithm combines quantitative measurements of Elecsys PIVKA-II assay and Elecsys AFP assay, plus age and gender to generate a semi-quantitative result. This study…

9 December 2022

A comparative analysis of Elecsys GALAD and Elecsys GAAD score to detect early-stage hepatocellular carcinoma in an international cohort

This study compared the clinical performance of the Elecsys GALAD (gender [sex], age, alpha-fetoprotein [AFP] Lens culinaris agglutinin-reactive fraction of AFP [AFP-L3] and protein-induced by vitamin…


You May Also Like

13 February 2024

The Pursuit for Better Patient Outcomes – Innovating HCC Management at Siriraj Hospital

Read More

Guiding the way: The role and value of algorithms in liver disease care journey

Read More
14 March 2023

Cost-effectiveness Analysis of GAAD algorithm on Hepatocellular Carcinoma Screening in Patients with Chronic Hepatitis B in China

This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic hepatitis B patients in…

Read More

Be the first to receive updates, event opportunities, and thought leadership insights.